Cardiolipin Binds to CD1d and Stimulates CD1d-Restricted γδ T Cells in the Normal Murine Repertoire

Mélanie Dieudé, Harald Striegl, Aaron J. Tyznik, Jing Wang, Samuel M. Behar, Ciriaco A. Piccirillo, Jerrold S. Levine, Dirk M. Zajonc and Joyce Rauch

J Immunol 2011; 186:4771-4781; Prepublished online 9 March 2011;
doi: 10.4049/jimmunol.1000921
http://www.jimmunol.org/content/186/8/4771

Supplementary Material
http://www.jimmunol.org/content/suppl/2011/03/07/jimmunol.1000921.DC1

References
This article cites 57 articles, 22 of which you can access for free at:
http://www.jimmunol.org/content/186/8/4771.full#ref-list-1

Why The JI? Submit online.
• Rapid Reviews! 30 days* from submission to initial decision
• No Triage! Every submission reviewed by practicing scientists
• Fast Publication! 4 weeks from acceptance to publication

Subscription Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Cardiolipin Binds to CD1d and Stimulates CD1d-Restricted γδ T Cells in the Normal Murine Repertoire

Mélanie Dieudée,*1 Harald Striegl,† Aaron J. Tyznik,‡ Jing Wang,† Samuel M. Behar,§ Ciriaco A. Piccirillo,¶ Jerrold S. Levine,‖,‡ Dirk M. Zajonc,‡,*2 and Joyce Rauch*,*1

Cardiolipin (CL), a major phospholipid in bacterial cell walls, is sequestered from the immune system in mammalian mitochondria and is, therefore, a potential danger signal. Based on growing evidence that phospholipids constitute natural ligands for CD1d and that CD1d-restricted T cells recognize phospholipids, we hypothesized that CD1d binds and presents CL and that T cells in the normal immune repertoire respond to CL in a CD1d-restricted manner. We determined the murine CD1d-CL crystal structure at 2.3 Å resolution and established through additional lipid loading experiments that CL, a tetra-acylated phospholipid, binds to murine CD1d with two alkyl chains buried inside the CD1d binding groove and the remaining two exposed into the solvent. We furthermore demonstrate the functional stimulatory activity of CL, showing that splenic and hepatic γδ T cells from healthy mice proliferate in vitro in response to mammalian or bacterial CL in a dose-dependent and CD1d-restricted manner, rapidly secreting the cytokines IFN-γ and RANTES. Finally, we show that hepatic γδ T cells are activated in vivo by CD1d-bearing dendritic cells that have been pulsed with CL, but not phosphatidylcholine. Together, these findings demonstrate that CD1d is able to bind and present CL to a subset of CL-responsive γδ T cells that exist in the spleen and liver of healthy mice and suggest that these cells could play a role in host responses to bacterial lipids and, potentially, self-CL. We propose that CL-responsive γδ T cells play a role in immune surveillance during infection and tissue injury. The Journal of Immunology, 2011, 186: 4771–4781.

Major histocompatibility complex and MHC-like proteins, including CD1, present distinct antigenic structures to T cells in response to microbial infections or cellular damage. Whereas MHC molecules present peptides from protein Ags, CD1 molecules present lipid and glycolipid molecules (1–5). The Ags that bind naturally to CD1 remain poorly elucidated, but include both self- and microbial ligands. Recognition of microbial lipid or glycolipid ligands underlies the innate-like antimicrobial functions mediated by activation of CD1-restricted T cells, which is characterized by the massive and rapid release of multiple cytokines and chemokines.

A growing body of evidence demonstrates that phospholipids constitute natural ligands for CD1. Glycerophospholipids, including phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine (PC), phosphatidylglycerol, phosphatidylserine, phosphatidylinositol (PI), and cardiolipin (CL), were found to be one of the two major categories of cellular lipids bound to human CD1d (6). Crystallographic studies of CD1d bound to PC (7) or PI dimannoside (PIM2) (8) demonstrate that such complexes can exist, whereas functional studies have shown that both αβ and γδ T cells can recognize phospholipids in a CD1d-restricted manner (9–11). Both natural and synthetic phospholipids are recognized by CD1-restricted T cells: phosphatidylethanolamine and PI are stimulatory to some murine CD1d (mCD1d)-restricted NKT cell hybridomas (12, 13); pollen phospholipids (including phosphatidylethanolamine and PC) are strong activators of human γδ CD1d-restricted T cells, inducing the production of both IFN-γ and IL-4 (10, 14); endogenous and exogenous phospholipids activate dendral γδ T cells in a CD1d-restricted manner, inducing the production of IL-4 and TGF-β (11); and lyso-PC stimulates GM-CSF and IFN-γ responses by human NKT cell clones and freshly isolated PBLs, respectively (15). Finally, CL has been shown to

*Mélanie Dieudée, Harald Striegl, Aaron J. Tyznik, Jing Wang, Samuel M. Behar, Ciriaco A. Piccirillo, Jerrold S. Levine, Dirk M. Zajonc, and Joyce Rauch contributed equally to this work.

†Division of Rheumatology, Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec H3G 1A4, Canada; ‡Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; §Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; ¶Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; ‖Department of Microbiology and Immunology, McGill University, Montreal, Quebec H3A 2B4, Canada; ′Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612; and ‡Section of Nephrology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612

Current address: Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montreal, Quebec, Canada.

1Current address: Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montreal, Quebec, Canada.

2D.M.Z. and J.R. contributed equally to this work.

Received for publication March 22, 2010. Accepted for publication February 2, 2011.

This work was supported by Canadian Institutes of Health Research Operating Grants MOP-42391 (to J.R.) and MOP-67101 (to J.R.), Institute of Musculoskeletal Health and Arthritis Priority Announcement MUS-67101 (to J.R.), National Institutes of Health Grants AI074952 (to D.M.Z.) and HL 080330 (to S.M.B.), a Genzyme Renal Innovations Program award (Genzyme Corporation to J.S.L.), an investigator award from the Cancer Research Institute (to D.M.Z.), and postdoctoral fellowships from the Research Institute of the McGill University Health Centre (to M.D.), the Department of Medicine of McGill University (to M.D.), and the National Institutes of Health (F32 AI 80087 to A.J.T.).

The structure factors and coordinates presented in this article have been submitted to the Protein Data Bank (http://www.pdb.org/pdb/home/home.do) under access number 3MA7.

Address correspondence and reprint requests to Dr. Joyce Rauch or Dr. Dirk M. Zajonc, Montreal General Hospital, 1650 Cedar Avenue, Room A6 148, Montreal, Quebec H3G 1A4, Canada (J.R.) or Division of Cell Biology, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037 (D.M.Z.). E-mail addresses: joyce.rauch@mcgill.ca (J.R.) and dzajonc@liai.org (D.M.Z.)

The online version of this article contains supplemental material.

Abbreviations used in this article: BMDC, bone marrow-derived dendritic cell; CL, cardiolipin; α-GalCer, α-galactosylceramide; hCL, hydrogenated cardiolipin; IEF, isoelectric focusing; KO, knockout; mCD1d, murine CD1d; MHC I, MHC class I; MHC II, MHC class II; PC, phosphatidylcholine; PDB, Protein Databank; PI, phosphatidylinositol; PIM2, phosphatidylinositol dimannoside; TM, tetramyristoyl; WT, wild-type.

Copyright © 2011 by The American Association of Immunologists, Inc. 0022-1767/11/16.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.11000921

Downloaded from http://www.jimmunol.org/ by guest on April 30, 2022
stimulate a murine γδ T cell hybridoma (16, 17), but neither CD1 restriction nor generalizability to ex vivo T cells was assessed. Synthetic CL was not stimulatory to human NKT cell clones, but it efficiently blocked CD1d presentation of an antigenic glycolipid (15). Taken together, these findings suggest that phospholipids can serve as natural ligands for CD1d and induce strong CD1d-restricted T cell responses.

CL is a unique phospholipid that can be of both mammalian and bacterial origin. In prokaryotic cells, particularly Gram-negative bacteria, CL is a major phospholipid component of the cell membrane. In contrast, in eukaryotic cells, CL is absent from the cell membrane, but accounts for as much as 20% of mitochondrial lipid (because of its bacterial symbiotic origin). Thus, in healthy mammalian cells, CL is normally sequestered from the immune system.

The presence of CL in prokaryotic cell membranes, along with its presence in healthy eukaryotic cell membranes, suggests that prokaryotic CL may serve as a danger signal to the mammalian immune system. It is not clear, however, whether eukaryotic mitochondrial CL is normally presented to the immune system in the context of CD1d, similar to MHC class I (MHC I) presentation of peptides from mitochondrial self-proteins (18). We hypothesize that by binding to CD1d, CL constitutes an important signal that induces a CD1d-restricted innate-like immune response to pathogens. In this study, we demonstrate that CL is a natural ligand for CD1d and that the normal immune repertoire contains CD1d-restricted T cells that are responsive to this phospholipid Ag.

Materials and Methods

Phospholipid preparation

Phospholipids and disulfatide (3,6-di-O-sulfo-β-D-galactosylcera- mide) were obtained from Avanti Polar Lipids (Alabaster, AL) and used without further purification. For lipid binding and crystallography studies, phospholipids were dissolved in either chloroform (CHCl₃) at 7.5 mg/ml or ethanol at 4 mg/ml, whereas disulfatide was dissolved in DMSO at 5 mg/ml. For cellular studies, lyophilized phospholipids dissolved in CHCl₃, or ethanol at 4 mg/ml, whereas disulfatide was dissolved in DMSO at 5 mg/ml. Diffraction data from a single crystal were collected at Beamline 7.1 of the Stanford Synchrotron Radiation Laboratory and processed to 2.3 Å with the Denzo-Scallop suite (20) in space group P1 (unit cell dimensions: a = 46.8 Å; b = 50.9 Å; c = 103.2 Å; α = 105.1; β = 92.2; γ = 106.2). Two CD1d–lipid complexes occupy the asymmetric unit with an estimated solvent content of 48.6%, based on a Matthews’ coefficient (Vₐ) of 2.39 Å³/Da. Molecular replacement in P1 was carried out in CCP4 (21) using the program MOLREP (22) and the CD1d-sulfatide structure (2AKR) as the search model, with the ligand removed, and resulted in a crystallographic R factor (R₁) of 38.0% and a correlation coefficient of 0.6. The initial refinement included several rounds of restrained refinement against the maximum likelihood target in REFMAC 5.2. At a later stage of refinement, carbohydrates were built in at all three N-linked glycosylation sites of CD1d. Refinement progress was judged by monitoring the free R factor (Rfree) for cross-validation (23). The model was rebuilt into SigmaA for all peakbsized 2Fᵥ − F₁ and F₁ − F₂ difference electron density maps using the program COOT (24). Water molecules were assigned in COOT for >3σ peaks in an F₁ − F₂ map and retained if they satisfied hydrogen-bonding criteria and returned 2Fᵥ − F₁ density > 1σ after refinement in REFMAC. Starting coordinates for the TM-CL ligand were obtained from the Hetero-compound Information Centre Uppsala (compound CDL) and truncated at all four fatty acyl chains accordingly. The TM-CL library for REFMAC (25) was created using the Dundee PRODRG server (26). Final refinement steps were performed using the translation, libration, and screw-axis rotation displacement procedure in REFMAC (27), with a total of three anisotropic domains (α1-α2 domain, α3-domain, and β1-microglobulin), and resulted in improved electron density maps for the glycolipid ligand and a further drop in Rfree. The CD1d–TM–CL structure has a final R₁ = 23.2% and Rfree = 27.3%, and the quality of the model (Table II) (28) was excellent, as assessed with the program Molprobity (29). The Protein Databank (PDB) coordinates for the mCD1d–TM–CL structure are available at the PDB under accession number 3MA7. The software program PyMol (DeLano Scientific, Palo Alto, CA) was used to prepare Fig. 2. The PDB2PQR server (30) and the program APBS (31) were used to calculate the electrostatic surface potentials in Fig. 2.

In vitro loading of lipid Ags

Aliquots of 10 µl purified mCD1d at a concentration of 20 µM were loaded overnight at room temperature in the presence of four to six times molar excess of each ligand, PC and disulfatide were dissolved in DMSO (1 to 2 mg/ml), whereas all CL species were dissolved in ethanol (4 mg/ ml). Final concentration of DMSO and ethanol in the loading experiment did not exceed 3–5%. Loading was performed in the presence of 100 mM Tris-HCl (pH 7). After lipid loading, samples were centrifuged (14,000 × g, 10 min), and 4 µl supernatant was used for isoelectric focusing (IEF) analysis. CD1d–lipid complexes were separated using precast gels (PhastGel 5-8 IEF) and the PhastSystem (GE Healthcare Biosciences, Piscataway, NJ). Staining of mCD1d was performed with Coomassie blue, and successful lipid loading is identified by a gel shift of the mCD1d band in relation to the control lanes.

Marine T cell preparation

All animal experiments were conducted according to the relevant Canadian and international guidelines and were approved by the McGui University Animal Care Committee. Specific pathogen-free C57BL/6 mice were obtained from Harlan Sprague Dawley, and TCRβ-deficient mice (The Jackson Laboratory, Bar Harbor, ME) were bred in-house. CD1d⁺/− mice backcrossed for 12 generations (N12) in the C57BL/6J background, which were kindly provided by Drs. Peter van den Elzen and Rusung Tan (University of British Columbia), were originally derived by Drs. Falk and Mark Exley (Harvard Medical School) (32). Anesthetized mice were perfused through the heart with PBS (pH 7.3), and the perfused spleen and liver were harvested postmortem. T cells from spleen or liver were purified by negative selection using a murine T cell enrichment kit (EasySep; StemCell Technologies, Vancouver, BC, Canada). Total splenic or hepatic T cells (~98% CD3+ cells) were isolated by negative selection using magnetic beads (EasySep; CD19, CD4, and CD8, StemCell Technologies, Vancouver, BC, Canada). The isolated T cell population contained both γδ and γε T cell subsets. In certain experiments (where specified), isolated T cells were labeled with CFSE using the CellTrace CFSE Cell Proliferation Kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. In experiments using purified γδ T cells, the cells were isolated using a two-step TCRγδ+ T cell isolation kit (Miltenyi Biotec, Auburn, CA). Briefly, a first-step enrichment of T cells by negative selection (removal of CD11b- and CD45R-negative cells) was followed by positive selection of TCRγδ-positive cells.
**T cell stimulation with phospholipids**

Purified total T cells (50 μl; 2.5 × 10^6/ml) or γδ T cells (50 μl; 1 × 10^7/ml) were stimulated with different final concentrations of phospholipids (30–60 μl of a 1 mg/ml suspension), including native bovine heart CL (also referred to as bovine CL, native CL, or CL), hydrogenated CL (hCL), or bovine heart PC, diluted in complete RPMI 1640 medium, in presence of APCs (splenocytes treated with mitomycin C; 150 μl; 8 × 10^6/ml). The cells were cultured in a 96-well plate for 24 or 48 h at 37°C (5% CO₂). Blocking experiments were performed using anti–I-A (Y3P; generously provided by Dr. Philippa Marrack, Howard Hughes Medical Institute, National Jewish Medical and Research Center, Denver, CO), anti-CD1d (19G11) (33), or anti-H2D₂ (34-2-12; BD Biosciences, Mississauga, ON, Canada). Cell proliferation was measured using a BrdU labeling kit (Roche Diagnostics, Indianapolis, IN) or CFSE-labeled cells. T cells were characterized by flow cytometry using mAbs to murine CD3, IFN-γ, αβ TCR, and γδ TCR (BD Biosciences). In certain studies (where specified), cells were stained with mAbs to murine CD25, CD69, Vg2, Vγ3, Vγ4, or Vδ6/3/2, Annexin V; and/or 7-aminoactinomycin D (BD Biosciences). To ensure intertube comparability, relative cell numbers were determined by adding 3000 True-Count bead events (BD Biosciences) to each tube prior to flow cytometry analysis and counting 500 True-Count bead events per sample during flow cytometry acquisition. These beads serve as an independent and absolute counting control to ensure that equivalent volumes are counted for each tube (independent of cell composition or number).

**In vivo γδ T cell response and flow cytometry**

Mouse bone marrow-derived dendritic cells (BMDCs) were prepared by culturing bone marrow progenitors with 20 μg/ml GM-CSF (PeproTech) for 7 days following standard protocols. On day 7, BMDCs were washed, counted, and cultured with phospholipid or vehicle control (100 μg/ml) for 24 h. After being washed with PBS, phospholipid-pulsed BMDCs (5 × 10^5) were injected i.v. into mice. Concurrently, mice were injected i.p. with 1 mg BrdU (BD Pharmingen). Liver mononuclear cells positive for CD3 were injected i.v. into mice. Concurrently, mice were injected i.p. with cells were cultured in a 96-well plate for 24 or 48 h at 37°C (5% CO₂). National Jewish Medical and Research Center, Denver, CO), anti-CD1d provided by Dr. Philippa Marrack, Howard Hughes Medical Institute, Blocking experiments were performed using anti–I-A (Y3P; generously provided by Dr. Philippa Marrack, Howard Hughes Medical Institute, National Jewish Medical and Research Center, Denver, CO), anti-CD1d (19G11) (33), or anti-H2D₂ (34-2-12; BD Biosciences, Mississauga, ON, Canada). Cell proliferation was measured using a BrdU labeling kit (Roche Diagnostics, Indianapolis, IN) or CFSE-labeled cells. T cells were characterized by flow cytometry using mAbs to murine CD3, IFN-γ, αβ TCR, and γδ TCR (BD Biosciences). In certain studies (where specified), cells were stained with mAbs to murine CD25, CD69, Vg2, Vγ3, Vγ4, or Vδ6/3/2, Annexin V; and/or 7-aminoactinomycin D (BD Biosciences). To ensure intertube comparability, relative cell numbers were determined by adding 3000 True-Count bead events (BD Biosciences) to each tube prior to flow cytometry analysis and counting 500 True-Count bead events per sample during flow cytometry acquisition. These beads serve as an independent and absolute counting control to ensure that equivalent volumes are counted for each tube (independent of cell composition or number).

**Results**

**Crystal structure of cardiolipin bound to mouse CD1d**

mCD1d is known to bind diacylated glycolipids and phospholipids (34), but its ability to bind tetra-acylated phospholipids has not been studied. Recently, CL, among other lipids, has been identified by mass spectrometry as a natural human CD1d ligand (6). However, CL does not appear to be an Ag for human invariant NKT cells, as it failed to activate a panel of human iNKT cell clones (15). To determine whether mCD1d is able to bind to CL, a tetra-acylated phospholipid with two negatively charged phosphate groups, we performed ligand binding studies with recombinant mCD1d and native (bovine heart) and synthetic (TM [14:0]) forms of CL. We also evaluated hCL to determine whether fatty acid chain saturation has an influence on CD1d binding. Bovine heart PC, which was derived from the same source as native CL and had similar fatty acid saturation, served as a control for mCD1d in the presence of a neutral phospholipid. Binding of CL to mCD1d was assessed by native IEF gel electrophoresis (Fig. 1A). Upon incubation of mCD1d with native bovine CL or synthetic TM-CL, but not fully saturated bovine hCL, two major bands were apparent (Fig. 1A, left panel). The lower band corresponds to mCD1d containing an uncharged endogenous spacer lipid derived from its expression in insect cells (net charge 0), whereas the upper fainter band corresponds to mCD1d–CL complexes (net charge −2). In addition, purified mCD1d also contains a faint double band above the major species of mCD1d. This double band is likely a result of endogenous ligands with different charge values bound to mCD1d, as it disappears upon loading with disulfatide (Fig. 1A, left panel, positive control). The mCD1d

![FIGURE 1.](http://www.jimmunol.org/.../44773)
preparation used for the lipid loading experiment is shown in the middle and right panels (Fig. 1A) and is more homogeneous and does not contain endogenously bound charged lipids. These findings demonstrate that recombinant mCD1d protein binds native bovine CL and TM-CL (band at ~2 net charge), but does not bind saturated bovine hCL. mCD1d incubated with buffer or neutrally charged bovine heart PC showed a major band for the CD1d endogenous spacer lipid (net charge 0), but no band with a net charge of ~2. Notably, binding of TM-CL and bovine CL occurred in the absence of lipid transfer proteins (none were present in the system), although binding was less efficient than that of the positive control (disulfatide with only two alkyl chains). We evaluated whether mCD1d could also bind bovine CL that had one (monolysyl-CL) or two (dilysyl-CL) fatty acyl chains removed (Fig. 1A, middle panel). mCD1d bound both lysos forms of CL, and binding was maximal with dilysyl-CL and appeared to decrease with the addition of fatty acyl chains. These data indicate that maximal binding of CL to mCD1d occurs with only two alkyl chains and that additional alkyl chains are not required for binding to mCD1d, although they could be required for recognition.

mCD1d–TM–CL complexes, purified using anion exchange (MonoQ) chromatography, showed a single band on IEF gel electrophoresis (Fig. 1A, right panel), with the same migration as purified complexes of mCD1d and disulfatide (the control for mCD1d loaded with a nonphospholipid Ag having a net ~2 charge) and were used for subsequent crystallization. These findings suggest that CL (bovine CL and TM-CL), despite the presence of four alkyl chains (Fig. 1B), can still bind to mCD1d and form a stable mCD1d–CL complex. The chemical structure of TM-CL raises the question whether TM-CL can bind simultaneously to two mCD1d molecules by inserting two alkyl chains in each of the CD1d binding grooves. However, size-exclusion chromatography revealed that one TM-CL molecule is bound by only one mCD1d protein molecule (data not shown).

To identify how CL binds to mCD1d, we crystallized mCD1d–CL complexes and determined the crystal structure to 2.3 Å resolution (Fig. 2, Table I). No gross structural differences in mCD1d are observed when comparing mCD1d–TM–CL (PDB ID 3MA7) to other mCD1d–glycolipid complexes (8, 19, 35–37). Two of the four alkyl chains are inserted into the A’ and F’ pockets of the CD1d binding groove (Fig. 2A), whereas the other two alkyl chains are exposed to the solvent. The central phosphate-glycerol-phosphate moiety of TM-CL is located above the binding groove in a position similar to the head groups of other glycolipid ligands (8, 19, 35–37). No clear electron density is observed for the two solvent-exposed alkyl chains of TM-CL, indicating that these chains make no major contact with CD1d residues and are disordered. Therefore, these two solvent exposed alkyl chains were not built into the final structure and are not depicted in Fig. 2. It is important to note that we observed a cavity within the crystal lattice. This cavity is big enough to accommodate the third and fourth alkyl chains. Moreover, it is clear from our ligand binding and size-exclusion chromatography experiments (Fig. 1A and data not shown) that one intact tetra-acylated TM-CL molecule binds to one CD1d molecule and that fully loaded mCD1d–TM–CL complexes have been purified and crystallized. Interestingly, there are no CD1d residues capable of neutralizing the negative charge of both phosphate groups of TM-CL. Despite this, mCD1d residues Asp80, Asp153, and Thr156 interact with the polar center of TM-CL through hydrogen bonding (Fig. 2C), thereby stabilizing the polar core of TM-CL and giving rise to very well-ordered electron density (Fig. 2B). In addition, two water molecules pro-

![FIGURE 2. Schematic representation of the mCD1d–CL complex. A, TM-CL (yellow) is bound in the hydrophobic binding groove between the α1 and α2 helices of the mCD1d H chain (gray), which noncovalently associates with β2-microglobulin (β2M, gray). Two N-linked glycosylation sites (N42 and N165) carry well-ordered carbohydrates (green sticks). A spacer lipid (C14, cyan) is present in the binding groove to complement the shorter C14-alkyl chains of the synthetic CL. B, The 2F~0~F~c~ electron density map is contoured at 1σ and shown as a blue mesh around the CL ligand. The third and fourth acyl chains, as well as the connecting glycerol, are not ordered in the crystal structure, and only 11 carbons of the myristoyl chain that binds in the A’ pocket are ordered. C, Hydrogen-bond interactions between CD1d residues (gray) and the polar moieties of CL (yellow) are represented. In addition, two water molecules also hydrogen bond with the two phosphate groups of CL. D, Comparison between the presentation of TM-CL (yellow) and α-GalCer (cyan) by mCD1d. E, Comparison between the presentation of CL (yellow) and sulfatide (green) by mCD1d. The central phosphate-glycerol-phosphate moiety of CL is located farther above the binding groove as compared with the more intimate binding of α-GalCer (the predominant invariant NKT cell Ag). However, the polar groups of both CL and sulfatide occupy similar positions. Notably, the terminal phosphate of CL is in a similar position as the sulfate of sulfatide. Binding comparison between TM-CL (yellow sticks) and PIM2 (thin green sticks) (F) and between TM-CL and PC (thin cyan sticks) (G). Protein backbone is colored accordingly, and side chains are shown for Arg79 (R79) and Asp80 (D80) for orientation. Surface representation, with electrostatic potential (red, electronegative, and blue, electropositive, contoured from ~30 to +30 kT/e), is shown in D and E. Several amino acid residues, which are involved either in the shaping of the mCD1d-binding grooves (B, D, E) or in polar interactions with CL (C), are depicted using the single letter amino acid code with the relevant residue number. Individual atoms are colored as follows: carbon, yellow, green, or cyan; oxygen, red; nitrogen, blue; phosphorus, purple; and sulfur, orange.](http://www.jimmunol.org/)
above a slightly electropositive patch formed by the Glu154 and mCD1d ligands to mCD1d follows a similar pattern in which the termination of the diacylglycerolipid backbone, similar to the binding of the glycosphingolipid backbones, in general, appears less conserved than the binding of the glycosphingolipid backbone while presenting the polar moieties for recognition by specific T cells.

Murine T cells proliferate in response to CL in a dose-dependent manner and produce IFN-γ

To determine whether CL-reactive T cells are found in the immune repertoire of healthy, untreated mice, we studied total spleen- and liver-derived T cells. Both splenic and hepatic T cells from C57BL/6 mice proliferated in response to the maximal concentration of native bovine CL (0.2 μM), but only hepatic T cells showed a dose-dependent response at lower concentrations of CL (i.e., ≤0.1 μM) (Fig. 3A). Moreover, the maximal proliferative response of hepatic T cells was >3-fold higher than that of splenic T cells (OD₄₅₀ = 1.086 ± 0.110 and 0.333 ± 0.100, respectively).

Table I. Data collection and refinement statistics for the CD1d–CL complex

<table>
<thead>
<tr>
<th>Statistics</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data collection</td>
<td></td>
</tr>
<tr>
<td>Resolution range (Å)</td>
<td>50.0–2.3 (2.38–2.30)</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>95.4 (88.4)</td>
</tr>
<tr>
<td>No. of unique reflections</td>
<td>37,815</td>
</tr>
<tr>
<td>Redundancy</td>
<td>1.9</td>
</tr>
<tr>
<td>Rsym (%)</td>
<td>9.1 (38.4)</td>
</tr>
<tr>
<td>I/σI (%)</td>
<td>12.9 (1.9)</td>
</tr>
<tr>
<td>Refinement statistics</td>
<td></td>
</tr>
<tr>
<td>No. of reflections (f &gt; 0)</td>
<td>36,507</td>
</tr>
<tr>
<td>Maximum resolution (Å)</td>
<td>2.3</td>
</tr>
<tr>
<td>Rmerge (%)</td>
<td>23.2 (31.2)</td>
</tr>
<tr>
<td>Rfree (%)</td>
<td>27.3 (32.7)</td>
</tr>
<tr>
<td>No. of proteins</td>
<td>6,282</td>
</tr>
<tr>
<td>Protein</td>
<td>5,899</td>
</tr>
<tr>
<td>Glycolipid/Spacer lipid</td>
<td>92/36</td>
</tr>
<tr>
<td>N-linked carbohydrate</td>
<td>98</td>
</tr>
<tr>
<td>Water</td>
<td>157</td>
</tr>
<tr>
<td>Ramachandran statistics (%)</td>
<td></td>
</tr>
<tr>
<td>Favored</td>
<td>96.8</td>
</tr>
<tr>
<td>Disallowed</td>
<td>0</td>
</tr>
<tr>
<td>Root mean square deviation from ideal geometry</td>
<td></td>
</tr>
<tr>
<td>Bond length (Å)</td>
<td>0.013</td>
</tr>
<tr>
<td>Bond angles (°)</td>
<td>1.5</td>
</tr>
<tr>
<td>Average B values (Å²)</td>
<td>46.9</td>
</tr>
<tr>
<td>Protein</td>
<td>66.7/48.3</td>
</tr>
<tr>
<td>Glycolipid/Spacer lipid</td>
<td>26.0</td>
</tr>
<tr>
<td>Carbohydrates</td>
<td>57.3</td>
</tr>
<tr>
<td>Disordered residues</td>
<td>C89-C92, C110-111, C201-202</td>
</tr>
</tbody>
</table>

Numbers in parentheses refer to the highest resolution shell.

^Numbers in parentheses refer to the highest resolution shell.

^Rmerge = Σ|Fobs|−|Fccl|/|Fobs|, where |Fobs| and |Fccl| are the observed and calculated structure factors, respectively, for all data.

^B values were calculated with the CCP4 program TLSANL (28).

Vide additional hydrogen-bond interactions with both phosphate groups of TM-CL.

We next compared the mCD1d binding of TM-CL to that of other mCD1d ligands, including α-galactosyl ceramide (α-GalCer), which stimulates Vα14-invariant NKT cells (35, 38); sulfatide, which stimulates a minor subset of non-Vα14 NKT cells (19, 39, 40); and two phosphoglycerolipids, PIM2 and PC (7, 8). The comparative structures (Fig. 2D–G) reveal that the lipid backbone of the various Ags binds slightly differently inside mCD1d and therefore leads to a slightly different presentation of the polar epitopes. Although binding of α-GalCer to mCD1d shows greater differences because of its α-linked galactose, binding of TM-CL and sulfatide to mCD1d follows a similar pattern in which the terminal phosphate of TM-CL, or sulfate of sulfatide, is located just above a slightly electropositive patch formed by the Glu154 and Gly155 backbones of the α-helix. When TM-CL binding to mCD1d is compared with either PIM2 or PC (Fig. 2F, 2G), the binding of all three phosphoglycerolipids appears quite similar. However, the binding of the diacylglycerolipid backbones, in general, appears less conserved than the binding of the glycosphingolipid backbones, which all superimpose very closely when bound by mCD1d (34, 41). The position of the proximal phosphate is slightly different in all three structures, and this orientation affects the presentation of the subsequent headgroup (Fig. 2F, 2G). In addition, the phosphoglycerolipids appear to bind in opposite orientations in the CD1d binding groove, leading to subtle differences in the binding orientation of the diacylglycerolipid backbone, similar to the binding of two α-galactosyl diacylglycerolipids from Borrelia burgdorferi to mCD1d (42). Although both TM-CL and PIM2 bind with the sn-1 linked fatty acid in the A’ pocket and the sn-2 linked acyl chain in the F’ pocket, the binding orientation of PC is reversed (Fig. 2F, 2G).

FIGURE 3. Murine splenic and hepatic T cells proliferate in response to CL in a dose-dependent manner and express IFN-γ. Purified T cells from spleen (left panels) or liver (right panels) of C57BL/6 mice were incubated with vehicle or phospholipid (cardiolipin [CL], hydrogenated CL [hCL], or phosphatidylcholine [PC]) in presence of APCs in vitro. Phospholipids were used at the following final concentrations: 0.015–0.2 μM (A), 0.2 μM (B), and 0.1 or 0.2 μM (C). A, Proliferation was evaluated by BrdU incorporation during the last 24 h of treatment. The data show the mean values (OD₄₅₀ ± SD of triplicate samples from one representative experiment of three independent experiments. Other controls (not shown) included Con A and cell medium, which had OD₄₅₀ (± SD) values of 1.194 (0.037) and 0.063 (0.004), respectively. B and C, IFN-γ production by CD3⁺ T cells was evaluated by flow cytometry in treated T cells at 0, 24, or 48 h. B shows the raw flow cytometry data from a representative experiment, whereas C shows the mean IFN-γ-positive T cells ± SD of three independent flow cytometry experiments (including the one in B).

The Journal of Immunology 4775
This is consistent with the fact that the liver contains a higher percentage of CD1-reactive T cells, such as NKT cells, than the spleen (43, 44). In contrast, we observed no significant proliferative response to hCL, a completely saturated form of bovine CL (Fig. 3A), in agreement with the finding that hCL did not bind to mCD1d (Fig. 1A). Similarly, PC, from the same source (bovine heart) as CL and with a high degree of fatty acid unsaturation, also failed to stimulate T cell proliferation (Fig. 3A), consistent with its inability to bind to mCD1d (Fig. 1A). We also evaluated whether monolysos-CL or dilyso-CL, potential breakdown products of bovine CL that lack one or two fatty acyl chains, respectively, could stimulate hepatic T cells. T cell proliferation was maximal with native CL and appeared to decrease with removal of fatty acyl chains (Supplemental Fig. 1A). These data indicate that maximal T cell proliferation occurs with the native form of the phospholipid and not with its breakdown products. To determine whether the T cell response was limited to bovine CL, we evaluated two other forms of CL: TM-CL (synthetic CL) and Escherichia coli CL (bacterial CL) (Supplemental Fig. 1B). TM-CL induced a low level of T cell proliferation, similar to that observed with dilyso-CL. In contrast, E. coli CL induced marked levels of T cell proliferation that were statistically indistinguishable from those seen with bovine CL (p < 0.8). These results suggest that murine hepatic T cells can differentiate between different forms of CL, but recognize both eukaryotic (bovine heart) and prokaryotic (E. coli) CL.

We next studied the time course of the T cell response to CL by monitoring IFN-γ expression of CD3+ T cells by flow cytometry. Purified splenic and hepatic T cells were stimulated for different periods of time with CL or other phospholipids (0.1 and 0.2 μM). Approximately 35.4% of splenic T cells treated with CL produced IFN-γ at 48 h, but far fewer cells (14.3%) produced IFN-γ at 24 h (Fig. 3B). In contrast, little or no IFN-γ production was detected in T cells treated with hCL or PC. Hepatic T cells were particularly responsive to CL treatment, and >5-fold IFN-γ-producing T cells were found in hepatic, compared with splenic, T cell preparations after treatment with 0.2 μM CL for 48 h (Fig. 3C). Maximal stimulation was observed with 0.2 μM CL at 48 h, with approximately half-maximal stimulation observed after 24 h. At 72 h, <25% of the CL-responsive T cells observed at 48 h were still viable (data not shown). These findings demonstrate that T cells proliferate and produce IFN-γ rapidly in a dose-dependent manner to CL. CL-responsive T cells are found predominantly in the liver, but are also detected in the spleen of healthy C57BL/6 mice.

**CL-responsive T cells express γδ TCR**

To determine the TCRs expressed by CL-responsive T cells, we monitored αβ and γδ TCR positivity of phospholipid-stimulated hepatic and splenic CD3+ T cells by flow cytometry. Vehicle-treated splenic and hepatic T cells were largely αβ TCR positive and γδ TCR negative (96.4 and 97.1%, respectively; Fig. 4A, 4B). In contrast, CL stimulation resulted in a reduction in αβ TCR+ CD3+ T cells and an increase in γδ TCR+ CD3+ T cells. Reduction in αβ TCR+ cells was due not to increased apoptosis (as detected by Annexin V and 7-aminoactinomycin D staining), but instead to a specific proliferation of γδ TCR+ cells (20.2% for CL versus 2.0% for vehicle) (Supplemental Fig. 2). These changes were specific to native CL and were not observed with hCL or PC. Stimulation of γδ TCR-bearing T cells was maximal in both hepatic and splenic T cells at 48 h, but the relative cell numbers (as defined in Materials and Methods) differed substantially (6367 [hepatic] versus 1029 [splenic]) (Fig. 4C) and suggest that there are ~6-fold more CL-responsive γδ T cells in the liver than spleen. When hepatic CL-responsive γδ T cells were evaluated for Vγ2, Vγ3, Vγ4, and Vδ6.3/2 expression, only Vγ3 expression was found to be significantly increased (2.4% compared with 0.3% in vehicle-stimulated cells) (data not shown). Taken together, our data indicate that CL-responsive cells are γδ T cells located more predominantly in the liver than in the spleen and suggest that Vγ2, Vγ4, and Vδ6.3/2 are not expressed on the predominant γδ T cell subset that responds to CL.

**CL-responsive γδ T cell expansion is independent of αβ T cells**

To exclude the possibility that αβ TCR-bearing cells (e.g., NKT cells) provide a first signal that induces a secondary γδ T cell response, we compared the responses of T cells from TCRβ-deficient and wild-type (WT) (C57BL/6) mice. As shown in Fig. 5A, splenic and hepatic T cells from TCRβ-deficient mice demonstrated strong proliferative responses to CL, similar to those of T cells from WT mice. The relative number of CL-responsive, IFN-γ-producing T cells found in the liver of TCRβ-deficient mice was also similar to that observed in WT mice (Fig. 5B, 5C). These results demonstrate that the proliferation of γδ T cells in response to CL is independent of the αβ T cell population and not secondary to activation of an αβ T cell subset. Furthermore, we have observed CL-specific stimulation of γδ T cells purified from spleen and liver of WT mice in the absence of any other cells...
CD1-induced expansion of \( \gamma \delta \) T cells was unaltered by the addition of anti-MHC I or anti-MHC II to APCs derived from C57BL/6 CD1d KO mice, whereas \( \gamma \delta \) T cells responsive to CL remained unaffected in the majority of the BrdU injected mice. \( \gamma \delta \) T cells derived from WT mice were unresponsive to CL presented by APCs from CD1d KO mice, but responded normally to CL presented by WT APCs (Fig. 6C, 6D). Furthermore, CL-responsive \( \gamma \delta \) T cells were undetectable in CD1d KO mice, whether APCs from CD1d KO or WT mice were used (Fig. 6C, 6D). The findings were the same whether detected by flow cytometry (\( \gamma \delta \) TCR, IFN-\( \gamma \) positivity) (Fig. 6C) or BrdU proliferation assay (Fig. 6D). Together, these data demonstrate that CL-responsive \( \gamma \delta \) T cells are restricted by CD1d and that CD1d is required for presentation of CL.

**CD1-restricted \( \gamma \delta \) T cells express the activation marker CD25 and produce RANTES and IFN-\( \gamma \) in response to CL**

To characterize the activation state of CL-responsive \( \gamma \delta \) T cells, we determined their expression of two activation markers (CD69 and CD25) 48 h poststimulation with CL (Supplemental Fig. 4). Stimulation of hepatic T cells with CL resulted in \( \gamma \delta \) TCR\(^{+} \) cells that were \( \geq 98\% \) negative for the expression of the early activation marker CD69. In contrast, a proportion (17.4\%) of these \( \gamma \delta \) TCR\(^{+} \) cells expressed CD25. Notably, IFN-\( \gamma \) expression was observed in 37.2\% of CD25\(^{+} \gamma \delta \) TCR\(^{+} \) cells compared with 5.2\% of CD25\(^{-} \gamma \delta \) TCR\(^{+} \) cells. These data indicate that CL-responsive IFN-\( \gamma \)-producing \( \gamma \delta \) T cells are clearly activated by CL and express the later activation marker, CD25, after 48 h of stimulation.

To investigate the potential biological effects of CL-responsive \( \gamma \delta \) T cells, we used an Ab array to examine the production of 22 cytokines and chemokines by hepatic T cells stimulated with CL, vehicle, or other phospholipids (Fig. 7A). Two cytokines, RANTES and IFN-\( \gamma \), were significantly elevated (>2-fold) in supernatants from CL-treated T cells compared with control cells (vehicle-, hCL-, or PC-treated). IL-4 was also detected in supernatants of vehicle-treated cells, but its presence was decreased by phospholipid treatment. Minimal levels of IL-13, IL-2, IL-12, soluble TNFR1, and TNF-\( \alpha \) were detected, but did not correlate with CL treatment. IFN-\( \gamma \) and RANTES levels in the supernatants of treated cells were 61.4 ± 0.7 ng/ml and 1563.8 ± 25.1 pg/ml, respectively, after treatment with 0.2 \( \mu \)M CL. Lower, but significantly elevated, levels of both cytokines (34.0 ± 4.7 ng/ml for IFN-\( \gamma \) and 244.6 ± 25.9 pg/ml for RANTES) were also observed with 0.1 \( \mu \)M CL (Fig. 7B). In contrast, only background levels (4.6 ± 0.1 ng/ml and 45.0 ± 4.4 pg/ml, respectively) of these cytokines were detected in supernatants of cells treated with hCL or PC (0.1 or 0.2 \( \mu \)M) (Fig. 7B). In parallel studies, 17.4\% of CL-responsive \( \gamma \delta \) T cells were shown to express the activation marker CD25 (data not shown). Taken together, our results show that hepatic \( \gamma \delta \) T cells are activated and secrete significant amounts of the cytokines IFN-\( \gamma \) and RANTES when stimulated by CL.

**CL activates \( \gamma \delta \) T cells in vivo**

To determine whether CL also stimulates \( \gamma \delta \) T cell in vivo, we injected mice that had received BrdU with BMDCs pulsed with CL or PC. Twenty-four hours later, we analyzed the expression of activation markers (CD25 and CD69) on CD3\(^{+} \gamma \delta \) TCR\(^{+} \) T cells in the liver. Injection of CL-pulsed BMDCs resulted in increased expression of CD25 on the proliferating BrdU\(^{+} \gamma \delta \) T cells in the liver (mean fluorescence intensity of 500, compared with 220 and 200 for vehicle and PC, respectively), whereas CD25 expression remained unaffected in the majority of the BrdU\(^{-} \) cells (Fig. 8). In contrast, PC-pulsed BMDCs did not induce the expression of activation markers on BrdU\(^{+} \) cells. Interestingly, this upregulation was observed in the liver and not the spleen, and upregulation of CD69 was not observed (data not shown). Importantly, the percentage of \( \gamma \delta \) T cells proliferating remained unaltered regardless of the phospholipid (CL or PC) used to pulse BMDCs (data not shown).
and D experiment of three independent experiments, whereas C population was evaluated by flow cytometry using TruCOUNT beads (phospholipid (PC, hCL, or CL), or vehicle, and APCs (from either WT or CD1 KO mice) for 48 h. Relative expansion of the CD3+, BrdU + T cells (data not shown). Furthermore, when Cd1d−/− BMDCs were pulsed with CL and injected into mice, we did not observe induction of CD25 on BrdU+ γδ T cells (data not shown).

Discussion

There is a growing body of evidence showing that CD1-restricted T cells recognize diacylated phospholipids (10, 11, 13). We demonstrate in this study that CD1d interacts specifically with CL, a tetra-acylated phospholipid. Moreover, we show that γδ T cells from the normal immune repertoire (particularly the liver) of healthy mice are stimulated by CL in a CD1d-dependent manner, proliferate rapidly, and secrete IFN-γ and RANTES. Our data suggest that CL-reactive γδ T cells could play a role in host responses to bacteria and, potentially, to self-CL by promoting IFN-γ- and RANTES-mediated responses.

We present in this paper the structure of mCD1d complexed with CL, which is, to our knowledge, the first structure of CD1d with a tetra-acylated phospholipid. Although the structures of several CD1d-glycolipid complexes have been determined, the structures of only two CD1d–phospholipid complexes have been elucidated: endogenously bound PC (7) and exogenously added PIM-2 (8). PC and PIM-2 bind in opposite orientations in the lipid-binding groove, indicating a less stringent binding orientation for glycerolipids in general, as compared with the binding of ceramide-based ligands, such as sulfatide and α-GalCer. CL, like PIM-2, binds with the sn-1 fatty acid inserted into the A’ pocket and the sn-2 fatty acid in the F’ pocket. In line with previous data on glycerolipid Ags from B. burgdorferi (42), we postulate that variations in the fatty acid composition of naturally occurring phosphoglycerolipids, such as length and saturation of the fatty acid (C14:0, C16:0, C18:0, C18:1, or C18:2), could influence the overall binding orientation of the glycerolipid in the binding groove of mCD1d, leading to subtle structural changes in the exposed T cell epitope and, possibly, altered T cell recognition. Although both bovine CL and TM-CL interacted with mCD1d, hCL did not. Chemically, hCL differs from native bovine CL only in the saturation of its fatty acid chains. Intriguingly, the role of the third and fourth alkyl chain of CL in T cell activation is currently unclear. On a molecular level, both exposed alkyl chains are flexible and can be accommodated between the CD1–TCR interface, similar to the squashed model that has been proposed for the highly exposed iGb3 ligand (37). Monolyso-CL and dilyso-CL (bovine CL with one and two fatty acids, respectively, removed) bound to mCD1d in our binding studies. However, lipid loading into CD1d is directly linked to the solubility of the lipid in question. Our findings for CD1d binding are consistent with this, in that binding/loading of dilyso-CL > monolyso-CL > TM-CL. In contrast, in T cell proliferation studies, dilyso-CL was only minimally stimulatory, and monolyso-CL was not stimulatory (and appeared to be toxic to the cells). These data suggest that the solvent-exposed third and fourth alkyl chains of CL may be important for T cell recognition and activation.

CL was recognized predominantly by hepatic, but also by splenic, γδ T cells. T cell stimulation occurred in a dose-dependent and CL-specific manner. Indeed, treatment with neither hCL nor PC induced similar T cell stimulation. In contrast, CL from both prokaryotic and eukaryotic cells was able to induce hepatic T cell proliferation to the same degree. The only difference between CL from different species is the fatty acid composition. Both E. coli CL and bovine CL are of natural origin and, as such, contain fatty acids that are both common (palmitic acid and stearic acid) and unique to prokaryotes (cyclopropyl fatty acids). Our...
limited data suggest that CL-reactive hepatic γδ T cells are not sensitive to the differences in fatty acid composition between eukaryotic and prokaryotic forms of CL, unlike invariant Vα14 NKT cells that have been reported to be sensitive to the fatty acid composition of B. burgdorferi α-galactosyl diacylglycerolipids (45) at least in part as a result of the two opposite binding orientations of the lipids observed inside the CD1d groove (42). To fully address the question of fatty acid specificity of murine hepatic γδ T cells, a panel of synthetic versions of prokaryotic and eukaryotic CL is required. In contrast to similar recognition of E. coli and mammalian CL, murine hepatic γδ T cells clearly differentiated between saturated (hCL) and unsaturated (native CL) forms of mammalian CL. CL from different organisms are not characterized by unique degrees of fatty acyl chain length or unsaturation (dominant fatty acids may vary in length between 14 and 22 carbon atoms and contain between 0 and 6 double bonds) (46). In light of these data, unsaturation is unlikely to be essential for the biological function of CL. However, as unsaturation tends to lower the transition temperature of a phospholipid, it can affect lipid solubility and fluidity. We have previously shown that CD1d-restricted recognition of phosphatidylethanolamine by an NKT cell hybridoma (24.8.A) is correlated with the degree of acyl chain unsaturation (13). Although it is tempting to speculate that CL induces γδ T cell activation because it is able to load more efficiently into the mCD1d molecule than hCL, it is equally possible that acyl chain unsaturation fine tunes the binding orientation of the phospholipid in the CD1d binding groove, leading to slight structural changes in the exposed T cell epitope, which, possibly, affects T cell recognition.

Our finding that CL is able to trigger the proliferation and activation of γδ T cells in vivo is consistent with data showing that CL is a major prokaryotic phospholipid expressed by many genera of bacteria (46). Thus, bacterial infections may result in circulating CL that could

**FIGURE 7.** CD1d-restricted γδ T cells produce RANTES and IFN-γ in response to CL. Purified hepatic T cells from C57BL/6 mice were incubated for 48 h in vitro with vehicle or 0.2 μM phospholipid (CL, hCL, or PC) in presence of APCs. A, Supernatants of treated cells were tested for the presence of 22 cytokines and chemokines using an Ab array quantitated by densitometry. Values indicate the signal intensity (%) relative to the presence of 22 cytokines and chemokines using an Ab array quantitated by densitometry. Values indicate the signal intensity (%) relative to the positive control (set at 100%) for each cell treatment. Error bars in A and B show data from a representative experiment of two independent experiments. Error bars in A and B indicate SD of the means of duplicate samples.

**FIGURE 8.** γδ T cells are activated by CL in vivo. C57BL/6 mice, which had received 1 mg BrdU i.p., were injected i.v. with 5 × 10^5 phospholipid- (CL or PC) or vehicle-treated BMDCs. A, BrdU^- (left panel) and BrdU^+ (right panel) populations of CD3^+ γδ TCR^+ liver mononuclear cells were analyzed for CD25 expression (open histograms) compared with vehicle-treated controls (shaded histograms) at 24 h. Histograms are representative plots of two independent experiments of two to four mice per group. B, Scatter plot of CD25 mean fluorescence intensity of two to four mice per group 24 h postinjection with phospholipid-pulsed BMDCs from a minimum of two independent experiments. A statistically significant difference (*p ≤ 0.001) was found for CL-pulsed compared with PC-pulsed BMDCs using the equal variance Student t test.
activated and secrete significant amounts of IFN-γ.

Indeed, transient increases of circulating human IFN-γ in response to an adaptive immune response can also induce the activation and proliferation of natural killer cells (55). Furthermore, RANTES is known to be secreted by certain T effector cells (56). We propose that exposure of γδ T cells to CL may create a proinflammatory hepatic microenvironment, resulting in potent antimicrobial responses implicated in immune surveillance.

CL-responsive T cells could also be expanded in the context of CL presentation as a self-Ag. Normally, CL is present in the inner mitochondrial membrane of eukaryotic cells (46). However, cell death or injury may result in CL being released or expressed on the cell surface (46). Exposure of endogenous CL, in a pathologic or nonphysiologic context, may constitute a danger signal and trigger a CL-specific γδ T cell response. Autimmune responses to CL and other phospholipids are known to occur in certain pathological contexts, such as systemic lupus erythematosus and antiphospholipid syndrome (57), and it is possible that CL-responsive γδ T cells may be activated in these disease states. To date, there are no published data on human CL-reactive γδ T cells. However, peripheral blood-derived CD1-restricted human γδ T cells recognize polylipid phospholipids (phosphatidylethanolamine and PC), produce both IFN-γ and IL-4, and provide help for IgE production (10, 14). Phosphatidylethanolamine and PC also activate human CD1-restricted duodenal γδ T cells, but the cytokines (IL-4 and TGF-β) they produce appear to be regulatory in nature (11). CL was not evaluated in the latter studies. Furthermore, little is known about the recognition of phospholipid by human splenic or hepatic γδ T cells.

In summary, we demonstrate that CL, a tetra-acylated phosphopolipid, is a natural ligand for mCD1d. Furthermore, we show that a subset of γδ T cells, found in the normal immune repertoire, is activated both in vitro and in vivo by CL in a CD1d-restricted manner and secretes IFN-γ and RANTES. We propose that prokaryotic, and possibly also eukaryotic, CL may serve as a danger signal for mammalian T cells. We further propose that CD1d-bound CL induces a potent innate-like immune response, which, through the release of IFN-γ and RANTES, promotes the transition to an adaptive immune response. In this manner, CL-reactive γδ T cells may play a key role in immune surveillance for CL expression during infection or tissue injury.

Acknowledgments

We thank Drs. Peter van den Elzen and Rusung Tan for providing the CD1d-deficient mice (originally derived by Drs. Steven Balk and Mark Exley) and Drs. Michel Lafleur and Gerhard Wingender for careful review and comments about the manuscript. We also thank Rebecca Subang and David Salem for technical assistance and Maria Da Silva Martins and Ekaterina Yurchenko for expert advice, assistance, and discussion in the later phase of the project. This paper is dedicated by Dr. Mélanie Dieudé to the memory of Rita Larochelle Boucher.

Disclosures

The authors have no financial conflicts of interest.

References


Downloaded from http://www.jimmunol.org/ by guests on April 30, 2022